Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
(1) To apply Bayesian statistics to screen for the most effective treatment regimen containing recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) for locally advanced or metastatic salivary gland ductal carcinoma expressing HER2 in the near future. (2) To explore biomarkers relevant to the efficacy of recombinant humanized anti-HER2 monoclonal antibody-MMAE-coupled vedicitumomab (Edisil, RC48) in the treatment of HER2-expressing locally advanced or metastatic salivary gland ductal carcinoma.
Epistemonikos ID: de12a543ddf34e5bc2d9d4e532e8c12e1fcaa4ea
First added on: Feb 19, 2024